Home LiteratureArticle Details
PMID: 10954555 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay.

Journal of virology ·Vol. 74 ·No. 18 ·2000-09-00 ·Pages 8541-9

Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, Sekaly RP, Kalams SA, Burchett SA, McIntosh K, Walker BD, Goulder PJ

Abstract

Human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte (CTL) responses play a major role in the antiviral immune response, but the relative contribution of CTL responses restricted by different HLA class I molecules is less well defined. HLA-B60 or the related allele B61 is expressed in 10 to 20% of Caucasoid populations and is even more highly prevalent in Asian populations, but yet no CTL epitopes restricted by these alleles have been defined. Here we report the definition of five novel HLA-B60-restricted HIV-1-specific CTL epitopes, using peripheral blood mononuclear cells in enzyme-linked immunospot (Elispot) assays and using CTL clones and lines in cytolytic assays. The dominant HLA-B60-restricted epitope, Nef peptide KEKGGLEGL, was targeted by all eight subjects with B60 and also by both subjects with B61 studied. This study additionally establishes the utility of the Elispot assay as a more rapid and efficient method of defining novel CTL epitopes. This approach will help to define new CTL epitopes that may play an important role in the immune control of HIV-1.

MeSH Terms
Adult Amino Acid Sequence Child Epitopes Gene Products, gag/immunology Gene Products, nef/immunology HIV Antigens/immunology HIV Core Protein p24/immunology HIV Envelope Protein gp41/immunology HIV-1/immunology HLA-B Antigens/immunology Histocompatibility Testing Humans Immunoenzyme Techniques/methods Molecular Sequence Data T-Lymphocytes, Cytotoxic/immunology Viral Proteins gag Gene Products, Human Immunodeficiency Virus nef Gene Products, Human Immunodeficiency Virus
Chemicals
Epitopes Gene Products, gag Gene Products, nef HIV Antigens HIV Core Protein p24 HIV Envelope Protein gp41 HLA-B Antigens HLA-B60 antigen HLA-B61 antigen Viral Proteins gag Gene Products, Human Immunodeficiency Virus nef Gene Products, Human Immunodeficiency Virus p17 protein, Human Immunodeficiency Virus Type 1
Authors & Affiliations
12 authors, click to expand affiliations / ORCID
Altfeld M A
Partners AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital and Harvard Medical School, Boston, USA.
Trocha A
Eldridge R L
Rosenberg E S
Phillips M N
Addo M M
Sekaly R P
Kalams S A
Burchett S A
McIntosh K
Walker B D
Goulder P J
References (41)
41 references, click to expand
  1. CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication.
    Adv Immunol. 1997;66:273-311 PMID: 9328644
  2. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development.
    J Immunol. 1997 Aug 15;159(4):1648-57 PMID: 9257824
  3. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection.
    J Immunol. 1998 Feb 1;160(3):1479-88 PMID: 9570570
  4. Diversity of HLA-B61 alleles and haplotypes in East Asians and Spanish Gypsies.
    Tissue Antigens. 1998 Apr;51(4 Pt 1):356-66 PMID: 9583807
  5. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.
    Science. 1999 Feb 5;283(5403):857-60 PMID: 9933172
  6. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.
    Science. 1999 Mar 12;283(5408):1748-52 PMID: 10073943
  7. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.
    J Exp Med. 1999 Mar 15;189(6):991-8 PMID: 10075982
  8. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy.
    Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3848-53 PMID: 10097126
  9. Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV.
    Immunol Lett. 1999 Mar;66(1-3):53-9 PMID: 10203034
  10. Consistent associations of HLA class I and II and transporter gene products with progression of human immunodeficiency virus type 1 infection in homosexual men.
    J Infect Dis. 1999 Aug;180(2):299-309 PMID: 10395843
  11. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection.
    J Virol. 1999 Aug;73(8):6715-20 PMID: 10400769
  12. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy.
    J Virol. 1999 Aug;73(8):6721-8 PMID: 10400770
  13. T lymphocyte responses in HIV-1 infection: implications for vaccine development.
    Curr Opin Immunol. 1999 Aug;11(4):451-9 PMID: 10448136
  14. The great escape - AIDS viruses and immune control.
    Nat Med. 1999 Nov;5(11):1233-5 PMID: 10545982
  15. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.
    Nat Med. 1999 Nov;5(11):1270-6 PMID: 10545993
  16. Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children.
    J Virol. 2000 Jun;74(12):5679-90 PMID: 10823876
  17. Anti-HIV cellular immunity: recent advances towards vaccine design.
    AIDS. 1999;13 Suppl A:S121-36 PMID: 10885771
  18. HIV-specific cytotoxic T lymphocytes in seropositive individuals.
    Nature. 1987 Jul 23-29;328(6128):345-8 PMID: 3496541
  19. Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency virus type 1.
    Proc Natl Acad Sci U S A. 1989 Dec;86(23):9514-8 PMID: 2480604
  20. An antigenic peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules.
    Eur J Immunol. 1989 Dec;19(12):2383-6 PMID: 2481593
  21. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells.
    J Immunol. 1991 Sep 1;147(5):1512-21 PMID: 1715361
  22. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
    J Virol. 1994 Jul;68(7):4650-5 PMID: 8207839
  23. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.
    J Virol. 1994 Sep;68(9):6103-10 PMID: 8057491
  24. Peptide motifs of HLA-B58, B60, B61, and B62 molecules.
    Immunogenetics. 1995;41(2-3):165-8 PMID: 7806292
  25. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype.
    J Immunol. 1995 Jan 15;154(2):685-93 PMID: 7529283
  26. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.
    J Exp Med. 1995 Apr 1;181(4):1365-72 PMID: 7699324
  27. Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP).
    Tissue Antigens. 1995 Feb;45(2):81-90 PMID: 7792765
  28. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression.
    Nat Med. 1995 Apr;1(4):330-6 PMID: 7585062
  29. HLA class I nucleotide sequences, 1995.
    Tissue Antigens. 1995 Sep;46(3 ( Pt 2)):217-57 PMID: 8525484
  30. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection.
    Nat Med. 1996 Apr;2(4):405-11 PMID: 8597949
  31. Three new cytotoxic T cell epitopes identified within the hepatitis C virus nucleoprotein.
    J Gen Virol. 1996 Jun;77 ( Pt 6):1305-9 PMID: 8683220
  32. HLA-B40, B18, B27, and B37 allele discrimination using group-specific amplification and SSCP method.
    Hum Immunol. 1996 Apr;46(2):107-13 PMID: 8727209
  33. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection.
    AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1691-8 PMID: 8959245
  34. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.
    Nat Med. 1997 Feb;3(2):205-11 PMID: 9018240
  35. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.
    Nat Med. 1997 Feb;3(2):212-7 PMID: 9018241
  36. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.
    Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1890-5 PMID: 9050875
  37. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
    J Immunol. 1997 Apr 1;158(7):3325-34 PMID: 9120290
  38. Serologic ambiguity and allelic frequency of the HLA-B40 family in the Korean population.
    Tissue Antigens. 1997 Apr;49(4):383-8 PMID: 9151390
  39. Combined structural and immunological refinement of HIV-1 HLA-B8-restricted cytotoxic T lymphocyte epitopes.
    Eur J Immunol. 1997 Jun;27(6):1515-21 PMID: 9209505
  40. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis.
    J Clin Invest. 1997 Aug 1;100(3):503-13 PMID: 9239396
  41. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.
    Science. 1998 Mar 27;279(5359):2103-6 PMID: 9516110
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/jvi.74.18.8541-8549.2000
Published
2000-09-00
Pages
8541-9
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC116366
Subset
IM
Grants
NIAID NIH HHS · U01 AI048023 · United States
NIAID NIH HHS · AI46995 · United States
NIAID NIH HHS · AI39966 · United States
NIAID NIH HHS · R37 AI028568 · United States
NIAID NIH HHS · R01 AI039966 · United States
NIAID NIH HHS · AI28568 · United States
NIAID NIH HHS · R01 AI046995 · United States
NIAID NIH HHS · R01 AI028568 · United States
NIAID NIH HHS · R01 AI030914 · United States
External Links
PubMed source DOI: 10.1128/jvi.74.18.8541-8549.2000 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2